Practical and Cost-Effective Manufacturing Route for the Synthesis of a β-Lactamase Inhibitor
摘要:
Compound 1, a potent and irreversible inhibitor of beta-lactamases, is in clinical trials with beta-lactam antibiotics for the treatment of serious and antibiotic-resistant bacterial infections. A short, scalable, and cost-effective route for the production of this densely functionalized polycyclic molecule is described.
Practical and Cost-Effective Manufacturing Route for the Synthesis of a β-Lactamase Inhibitor
摘要:
Compound 1, a potent and irreversible inhibitor of beta-lactamases, is in clinical trials with beta-lactam antibiotics for the treatment of serious and antibiotic-resistant bacterial infections. A short, scalable, and cost-effective route for the production of this densely functionalized polycyclic molecule is described.
A cautionary note on the use of p-nitrobenzenesulfonamides as protecting groups
作者:Peter G.M. Wuts、Jill M. Northuis
DOI:10.1016/s0040-4039(98)00684-4
日期:1998.6
regioselectivity. Cleavage requires addition of thiolate at the sulfonamide carbon, but some addition occurs at the nitro carbon resulting in simple displacement of the nitrogroup rather than sulfonamide cleavage. The side reaction is most prevalent with cyclic amines and stericeffects play only a limited role. This lack of regioselectivity is not observed for o-nitrobenzenesulfonamides.
Oxidative Debenzylation of <i>N</i>-Benzyl Amides and <i>O</i>-Benzyl Ethers Using Alkali Metal Bromide
作者:Katsuhiko Moriyama、Yu Nakamura、Hideo Togo
DOI:10.1021/ol501703y
日期:2014.7.18
The oxidative debenzylation of N-benzyl amides and O-benzyl ethers was promoted with high efficiency by a bromo radical formed through the oxidation of bromide from alkali metal bromide under mild conditions. This reaction provided the corresponding amides from N-benzyl amides and carbonyl compounds from O-benzyl ethers in high yields.
Practical and Cost-Effective Manufacturing Route for the Synthesis of a β-Lactamase Inhibitor
Compound 1, a potent and irreversible inhibitor of beta-lactamases, is in clinical trials with beta-lactam antibiotics for the treatment of serious and antibiotic-resistant bacterial infections. A short, scalable, and cost-effective route for the production of this densely functionalized polycyclic molecule is described.